0 8

Cited 0 times in

Cited 0 times in

Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease

DC Field Value Language
dc.contributor.author장지석-
dc.date.accessioned2026-01-06T00:44:11Z-
dc.date.available2026-01-06T00:44:11Z-
dc.date.issued2025-12-
dc.identifier.issn0304-3835-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/209750-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science Ireland-
dc.relation.isPartOfCANCER LETTERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleRethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorFlorence T H Wu-
dc.contributor.googleauthorHeejoo Ko-
dc.contributor.googleauthorEmma M Dunne-
dc.contributor.googleauthorSarah Baker-
dc.contributor.googleauthorMitchell Liu-
dc.identifier.doi10.1016/j.canlet.2025.218106-
dc.contributor.localIdA04658-
dc.relation.journalcodeJ00448-
dc.identifier.eissn1872-7980-
dc.identifier.pmid41176209-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0304383525006780-
dc.contributor.alternativeNameChang, Jee Suk-
dc.contributor.affiliatedAuthor장지석-
dc.citation.volume635-
dc.citation.startPage218106-
dc.identifier.bibliographicCitationCANCER LETTERS, Vol.635 : 218106, 2025-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.